|12th February 2021||Fredric N Eshelman||2,875,000||Grant/award etc.||$7.29||$20,958,750.00|
|1st February 2021||Anthony Y Sun||13,077||Open or private sale||$37.23||$486,885.48|
|1st February 2021||Anthony Y Sun||12,417||Open or private sale||$37.68||$467,844.00|
|1st February 2021||Anthony Y Sun||1,300||Open or private sale||$38.54||$50,107.98|
|15th January 2021||Ernest Mario||41,216||Exercise of in-the-money or at-the-money derivatives securities (usually options)||$2.27||$93,560.32|
|2nd December 2020||Anthony Y Sun||6,283||Open or private sale||$52.70||$331,122.90|
|2nd December 2020||Anthony Y Sun||7,878||Open or private sale||$51.67||$407,021.60|
|2nd December 2020||Anthony Y Sun||3,411||Open or private sale||$49.79||$169,838.12|
|2nd December 2020||Anthony Y Sun||9,222||Open or private sale||$50.90||$469,361.07|
|24th November 2020||Anthony Y Sun||100||Open or private sale||$47.56||$4,756.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Edenovia, Inc. engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine.